Form 4 for NDRA ENDRA Life Sciences Inc.
Accepted 2026-01-23 00:00:00 ET · period of report 2026-01-21 · accession 0001193125-26-021412 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-23 | 2026-01-21 | NDRA | Basenese Lou | Dir | A - Grant | $0.00 | +60.3K | 65.7K | +1,120% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-21 | A | A | 60,324 | $0.00 | 65,709 | D | — | — | (F1) Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027. (F2) Includes unvested RSUs. |